2m 2m 2m 2m 2m 2m 2m
ERNEXA THERAPE (ERNA)
NASDAQ
$8.16+$0.16 (+1.95%)
Price as of Jun 03, 2026 7:43 PM EDT- $12.3MMarket Cap
- -88.13%1-Year Change
- BiotechnologyIndustry
ERNEXA THERAPE (ERNA)
$8.16+$0.16 (+1.95%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | 582,000 +755.88% | 68,000 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | 96,000 -59.32% | 236,000 N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 486,000 +389.29% | -168,000 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -4.2M -9.73% | -4.6M -22.23% | -5.9M -43.03% | -10.4M -18.21% | |
Depreciation and Amortization Expense | 65,000 -53.24% | 139,000 +65.48% | 84,000 -47.83% | 161,000 +37.61% | |
Total Operating Expenses | 9.3M -42.33% | 16.2M -22.93% | 21.0M -36.88% | 33.2M -70.79% | |
Operating Profit | -9.3M -40.54% | -15.7M -25.84% | -21.1M -36.37% | -33.2M -70.79% | |
Interest Income | 100,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -27,000 -99.60% | -6.8M +999.67% | -614,000 N/A | N/A N/A | |
Interest Income and Expense and Net | 73,000 +101.08% | -6.8M +999.67% | -614,000 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -4.8M -83.32% | -28.8M +5,279.66% | -536,000 -106.17% | 8.7M +199.25% | |
Income before Taxes | -14.1M -68.26% | -44.5M +105.39% | -21.7M -11.67% | -24.5M -79.97% | |
Income Taxes | -45,000 -250.00% | 30,000 +1,100.00% | -3,000 -106.67% | 45,000 -29.69% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -14.1M -68.34% | -44.5M +105.55% | -21.7M -11.84% | -24.6M -79.94% | |
Net Income from Continuing Operations Applicable to Common | -14.1M -68.35% | -44.6M +105.47% | -21.7M -11.84% | -24.6M -79.93% | |
Basic EPS and Net Income | -2.24 -31.29% | -3.26 -20.10% | -4.08 -49.38% | -8.06 +184.81% | |
Diluted EPS and Net Income | -2.24 -31.29% | -3.26 -20.10% | -4.08 -49.38% | -8.06 +184.81% | |
Basic Weighted Average Shares | 6.3M -53.78% | 13.6M +156.81% | 5.3M +74.17% | 3.1M -92.95% | |
Diluted Weighted Average Shares | 6.3M -53.78% | 13.6M +156.81% | 5.3M +74.17% | 3.1M -92.95% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 1.9M +8.96% | 1.7M -77.17% | 7.6M -33.82% | 11.4M -32.61% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 1.9M +8.96% | 1.7M -77.17% | 7.6M -33.82% | 11.4M -32.61% | |
Total Current Assets | 3.1M +33.21% | 2.4M -75.50% | 9.6M -29.84% | 13.7M -27.10% | |
Accumulated Depreciation | 197,000 +14.53% | 172,000 +50.88% | 114,000 +256.25% | 32,000 -84.54% | |
Property and Plant and Equipment and Net | 94,000 +10.59% | 85,000 -82.76% | 493,000 +108.90% | 236,000 -64.78% | |
Total Long-Term Assets | 110,000 -6.78% | 118,000 -1.67% | 120,000 -89.42% | 1.1M +69.25% | |
Total Assets | 5.8M +10.72% | 5.3M -89.28% | 49.1M +120.53% | 22.3M -29.33% | |
Income Taxes Payable | 3,000 0.00% | 3,000 +50.00% | 2,000 N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 4.1M 0.00% | 4.1M +134.29% | 1.8M N/A | |
Total Current Liabilities | 3.1M +5.96% | 2.9M -55.30% | 6.6M -14.12% | 7.7M +108.16% | |
Total Long-Term Debt | 10.9M +626.67% | 1.5M -77.85% | 6.8M +461.61% | 1.2M N/A | |
Total Long-Term Liabilities | 43,000 -61.26% | 111,000 +32.14% | 84,000 -10.64% | 94,000 +95.83% | |
Total Liabilities | 3.4M -3.78% | 3.6M -92.39% | 46.9M +361.06% | 10.2M +68.91% | |
Retained Earnings | -245.6M +6.09% | -231.5M +23.83% | -187.0M +13.12% | -165.3M +17.48% | |
Total Stockholders Equity | 2.4M +41.15% | 1.7M -23.82% | 2.2M -81.56% | 12.1M -52.53% | |
Total Shares Outstanding | 7.9M -84.72% | 51.4M +849.83% | 5.4M +5.52% | 5.1M -90.14% | |
Cash Flow | |||||
Cash from Operating Activities | -7.0M -55.69% | -15.8M -22.40% | -20.4M -2.71% | -21.0M -10.69% | |
Capital Expenditures | 37,000 -89.97% | 369,000 +1,842.11% | 19,000 -93.60% | 297,000 +92.86% | |
Cash from Investing Activities | -37,000 -89.86% | -365,000 +1,821.05% | -19,000 -59.57% | -47,000 -99.79% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 7.2M +15.16% | 6.3M -62.19% | 16.6M -15.44% | 19.6M -68.21% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | 83.51% +133.80% | -247.06% N/A | N/A N/A | |
Operating Margin | N/A N/A | -2,693.13% -91.34% | -31,080.88% N/A | N/A N/A | |
Return on Assets | -253.99% +55.11% | -163.74% +169.82% | -60.69% -33.58% | -91.36% -86.85% | |
Return on Equity | -687.47% -69.64% | -2,264.31% +649.27% | -302.20% +131.21% | -130.70% -85.95% | |
Revenue Growth | N/A N/A | 755.88% N/A | N/A N/A | N/A N/A | |
Current Ratio | 1.01 +25.72% | 0.80 -45.19% | 1.46 -18.29% | 1.79 -64.98% | |
Cash Ratio | 0.61 +2.84% | 0.59 -48.93% | 1.15 -22.94% | 1.50 -67.63% | |
Debt-to-Equity Ratio | N/A N/A | 3.29 -32.39% | 4.87 +1,893.94% | 0.24 N/A | |
Debt-to-Assets Ratio | N/A N/A | 1.06 +380.25% | 0.22 +66.77% | 0.13 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow